FDA Expecting 10 Biosimilar Applications Submitted By End Of FY 2015
The agency says it expects to receive three biosimilar marketing applications in fiscal year 2014 and another seven in FY 2015, as well as much more in program revenue.
You may also be interested in...
Pegfilgrastim product, a collaboration with the Indian firm Intas, may have to compete with multiple filgrastim products, along with its reference biologic, Amgen’s Neulasta.
After just one year of working with the U.S FDA, the South Korean company is positioning itself to launch its first monoclonal antibody biosimilar in the U.S. market.
Halfway through the first year of the biosimilar user fee program, fee payments have not lived up to the expectation in President Obama’s FY 2013 budget request. Initial meetings continue to grow but at a slow pace, suggesting sponsors may remain hesitant about the pathway.